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Economic Costs and Health-Related Quality of Life
Outcomes of HIV Treatment After Self- and Facility-Based
HIV Testing in a Cluster Randomized Trial
Hendramoorthy Maheswaran, PhD,*† Stavros Petrou, PhD,* Peter MacPherson, PhD,‡§
Felistas Kumwenda, MPH,† David G. Lalloo, PhD,†§ Elizabeth L. Corbett, PhD,†k and
Aileen Clarke, MD*
Background: The scale-up of HIV self-testing (HIVST) in Africa
is recommended, but little is known about how this novel approach
inﬂuences economic outcomes following subsequent antiretroviral
treatment (ART) compared with established facility-based HIV
testing and counseling (HTC) approaches.
Setting: HIV clinics in Blantyre, Malawi.
Methods: Consecutive HIV-positive participants, diagnosed by
HIVST or facility-based HTC as part of a community cluster-
randomized trial (ISRCTN02004005), were followed from initial
assessment for ART until 1-year postinitiation. Healthcare resource
use was prospectively measured, and primary costing studies undertaken
to estimate total health provider costs. Participants were interviewed to
establish direct nonmedical and indirect costs over the ﬁrst year of ART.
Costs were adjusted to 2014 US$ and INT$. Health-related quality of
life was measured using the EuroQol EQ-5D at each clinic visit.
Multivariable analyses estimated predictors of economic outcomes.
Results: Of 325 participants attending HIV clinics for assessment for
ART, 265 were identiﬁed through facility-based HTC, and 60 through
HIVST; 168/265 (69.2%) and 36/60 (60.0%), respectively, met national
ART eligibility criteria and initiated treatment. The mean total health
provider assessment costs for ART initiation were US$22.79 (SE: 0.56)
and US$19.92 (SE: 0.77) for facility-based HTC and HIVST participants,
respectively, and was US$2.87 (bootstrap 95% CI: US$1.01 to US$4.73)
lower for the HIVST group. The mean total health provider costs for the
ﬁrst year of ART were US$168.65 (SE: 2.02) and US$164.66 (SE: 4.21)
for facility-based HTC and HIVST participants, respectively, and
comparable between the 2 groups (bootstrap 95% CI: 2US$12.38 to
US$4.39). EQ-5D utility scores immediately before and one year after
ART initiation were comparable between the 2 groups. EQ-5D utility
scores 1 year after ART initiation had increased by 0.129 (SE: 0.011)
and 0.139 (SE: 0.027) for facility-based HTC and HIVST
participants, respectively.
Conclusions: Once HIV self-testers are linked into HIV services,
their economic outcomes are comparable to those linking to services
after facility-based HTC.
Key Words: HIV, HIV self-testing, ART, costs, health-related
quality of life, EQ-5D
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INTRODUCTION
There are now over 10 million Africans receiving
antiretroviral treatment (ART), the majority living in Eastern
and Southern Africa.1 Despite this impressive achievement,
over one half of HIV-positive individuals are still in need of
treatment, and over one million people become infected every
year.1 Meeting HIV elimination targets set by UNAIDS (“90-
90-90”) will require novel approaches and signiﬁcant invest-
ment in HIV testing and treatment services. HIV self-testing
(HIVST), deﬁned as an individual performing and interpret-
ing their own HIV test,2 is one potential solution, and its
scale-up in Africa is recommended.3
HIVST offers an opportunity for early engagement of
individuals in HIV services.4,5 However, there is limited
research around the cost implications and health-related quality
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of life (HRQoL) outcomes of HIV-positive individuals,
identiﬁed through HIVST, after entering HIV care, to inform
potential users and providers on the beneﬁts of HIVST. The
cost of providing HIVST is comparable to standard facility-
based HIV testing and counseling (HTC), but the lower yield
of positive individuals makes it more costly for identifying
those who are HIV-positive.6 In contrast to HIVST, facility
HTC services are more commonly accessed by those with
advanced HIV disease,4,7 with individuals needing additional
medical care to manage comorbidities.8,9 Engaging individuals
early within HIV care and treatment through HIVST may yield
later cost savings. Improvements in HRQoL among those
initiating ART after testing HIV-positive through facility HTC
services have been demonstrated10; this has yet to be shown for
those identiﬁed through HIVST. Accurate and contemporane-
ous understanding of these economic outcomes will be
essential to inform policy on scale-up.
We recruited a cohort of adults attending HIV treatment
clinics in Blantyre, Malawi, after they had undergone HIVST
or facility-based HTC. Our primary aim was to compare the
economic costs incurred by health providers and patients and
to compare health-related quality of life outcomes for adults
diagnosed through HIVST or facility-based HTC.
METHODS
Study Design and Participants
We undertook a prospective cohort study in Blantyre,
Malawi, between March 2013 and January 2015. We
recruited HIV-positive adults identiﬁed through either HIVST
or facility-based HTC who were participants of a cluster-
randomized trial investigating health outcomes of offering
HIVST (ISRCTN02004005).4,5 Ethical approval was
obtained from the College of Medicine Ethics Review
Committee, University of Malawi, and the University of
Warwick Biomedical Research Ethics Committee. All partic-
ipants provided informed consent.
The cluster-randomized trial comprised a population
of approximately 34,000 residents4–6 where adult HIV
prevalence was approximately 18%.11 Participants in control
clusters had access to routine facility-based HTC, and those
in intervention clusters were offered HIVST through resi-
dent community counselors in addition to facility-based
HTC. Participants who self-tested did not have to disclose
their HIV test result to community counselors but were
offered posttest counseling, advice on where to seek care
and a “self-referral card” for HIV clinics. HIVST was
provided in the intervention clusters for a 2-year period,
starting in February 2012.
We recruited participants from 3 HIV clinics located in
the study areas: Queen Elizabeth Central Hospital (QECH),
Ndirande Health Centre, and Chilomoni Health Centre. At
the start of this study, these clinics had initiated 19,929,
6656, and 4485 individuals onto ART.12 Eligible partic-
ipants were HIV-positive adults (aged $18 years) attending
for ﬁrst assessment for ART initiation and resident within
trial clusters (veriﬁed using global position system-based
“Map Book”13). Participants who had not accessed either
HIVST or facility-based HTC, or who had been assessed for
ART initiation or started ART at another location,
were excluded.
All care was provided by the routine health system.
HIV-positive individuals underwent CD4 count measure-
ments, tuberculosis (TB) screening, provision of cotrimox-
azole, and ART adherence counseling. Multiple visits may
have been required to complete this assessment. Those who
met Malawi national ART eligibility criteria (CD4 count
,350 cells/mm3 or WHO stage 3 or 4, or breastfeeding or
pregnant) were initiated onto ART.
Participants initiated onto ART returned to the HIV
clinic at regular intervals for assessment by clinic nurses [or
clinical ofﬁcers (available at all clinics), or doctors (available
at QECH only) if unwell]. At clinic visits, ART medication
was provided, adherence and response to treatment was
assessed, and other clinical problems (eg, TB) managed.
Visits varied in frequency, depending on response to ART.
We interviewed participants after each visit to the HIV
clinic, and if they were initiated onto ART, they were
followed-up for one year. On recruitment, the study team
administered structured questionnaires, recording age, sex,
marital status, educational attainment, employment status,
self-reported income, mode of HIV testing (HIVST, or
facility HTC), WHO clinical stage, CD4 count before starting
ART, and tracing details. Participants were deﬁned as lost to
follow-up if they did not return for scheduled clinic visits and
could not be traced.
Direct Health Provider Costs
After each visit to the HIV clinic, the study team used
structured questionnaires to record healthcare resources for
each participant, including medical personnel seen, inves-
tigations performed, and ART and other medications pre-
scribed. Resources related to hospitalization were not
available from participants’ HIV clinic records. Primary
resource-based costing was undertaken to estimate unit costs
for each resource input and consequently total direct health
provider costs.14,15 Appendix A, http://links.lww.com/QAI/
A996 provides a detailed description of the costing process,
and Appendix B, http://links.lww.com/QAI/A996 the esti-
mated unit costs estimated for healthcare resources from the
primary costing studies.
Direct Non-medical and Indirect Costs
An interviewer-administered questionnaire was also
used after each clinic visit to record participants’ direct
nonmedical and indirect costs and, where appropriate, costs
incurred by family member(s) or carer(s) who accompanied
them to clinic. Development, language translations, and pilot
testing of questionnaires followed previous procedures.6
Direct nonmedical costs included costs of transportation,
food, drinks, and other items bought as a consequence of
health center visits. For indirect costs, we recorded whether
participants or their carers had taken time off work, and
multiplied time by self-reported income.16 There are no
formal payments to access public health services in Malawi.
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Health-Related Quality of Life
The Chichewa EuroQoL EQ-5D-3L17 was used to
measure HRQoL after each clinic visit. Participants com-
pleted both the descriptive EQ-5D-3L system and the
accompanying visual analogue scale (VAS).18 Responses to
the 5 dimensions (mobility; self-care; usual activities; pain;
anxiety) of the EQ-5D-3L descriptive system were converted
into an EQ-5D utility score using a tariff. Tariff sets have
been derived from national surveys of the general population,
with a subset of the 243 health states being valued, most
commonly using the time trade-off method.18 As there is no
Malawian EQ-5D tariff, we used the Zimbabwean EQ-5D
tariff set to derive an EQ-5D utility score for each study
participant at each time point.19 The VAS is similar to
a thermometer and ranges from 100 (best imaginable health
state) to 0 (worst imaginable health state). Participants
recorded how good or bad their health was on the day of
the clinic visit by drawing a line on the scale.
Statistical Analysis
Analyses used Stata version 13.1 (Stata Corporation,
TX). Costs were converted into 2014 US Dollars and
International Dollars.20,21 International dollars are hypothet-
ical units of currency that take into account differences in
purchasing power across countries, thereby providing a means
of comparing cost estimates across jurisdictions. Principal
component analysis was used to generate wealth quintiles
combining socioeconomic variables, which included 9 house-
hold assets and home environment variables.22
We undertook multiple imputation using chained
equations to impute missing values for cost and HRQoL
estimates for participants lost to follow-up.23 Comparable to
previous studies, our imputation models included mode of
HIV testing received, baseline CD4 count, age, sex, and
socioeconomic variables.24,25 We used predictive mean
matching to impute missing values for cost and HRQoL
outcomes as they were nonnormally distributed, and to ensure
imputed costs were nonnegative.26
We estimated the total direct health provider cost, total
direct nonmedical and indirect cost, and total societal costs
for each study participant. For direct health provider costs,
we ﬁrst estimated total cost for clinic consultations, total
costs for investigations, and total costs for treatments. These
costs were summed to estimate total direct health provider
costs. Health provider costs only included the costs of
providing HIV and related medical care at the clinics. The
total societal cost was estimated by summing all direct and
indirect costs.
We estimated costs for 2 time periods. The ﬁrst was for
the ART assessment period. This included all costs from ﬁrst
attendance to the HIV clinic and continued until the clinic had
decided whether a participant was eligible for ART initiation.
The second was for the ﬁrst year on ART and included all
costs from the ﬁrst visit to be initiated onto ART until the
participant had been on ART for one year. We estimated
mean differences in these costs by mode of HIV testing using
bootstrap methods with 500 replications to estimate bias-
corrected 95% conﬁdence intervals (CI).27 We undertook
multivariable analysis to investigate the independent effects
of mode of HIV testing on costs. The multivariable model
was adjusted for age, sex, and other socio-demographic
variables, in addition to baseline CD4 count.8 We used
generalized linear models (GLM) and ran model diagnostics
to determine optimal choices for distributional family and link
functions.28
For HRQoL assessments, we estimated EQ-5D utility
and VAS scores immediately before ART initiation, and for
those who initiated ART, after one-year of treatment. We
estimated mean differences, and 95% bootstrapped CIs, in
FIGURE 1. Participant recruitment
and follow-up. *Malawi national ART
eligibility criteria during study
period: CD4 count ,350 cells/mm3;
WHO stage 3 or 4; breastfeeding; or
pregnant. **Loss to follow-up from
this health economic study.
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HRQoL outcomes by mode of HIV testing received. In
addition, we undertook multivariable analysis to investigate
the independent effects of mode of HIV testing and baseline
CD4 count on the EQ-5D utility scores. The multivariable
models were additionally adjusted for age, sex, and other
socio-demographic variables. As EQ-5D utility scores are
nonnormally distributed, negatively skewed and truncated at
1.0, we evaluated 4 commonly used estimators for our
TABLE 1. Characteristics of ART Assessed Participants
Facility HTC Participants, n (%) HIVST Participants, n (%) P*
All 265 60
Sex
Male 110 (41.5) 20 (33.3) 0.243
Female 155 (58.5) 40 (66.7)
Age, yr
18–24 32 (12.1) 11 (18.3) 0.430
25–39 169 (63.8) 36 (60.0)
40+ 64 (24.2) 13 (21.7)
Marital status
Single (never married) 19 (7.2) 4 (6.7) 0.884
Married/Cohabiting 183 (69.1) 39 (65.0)
Separated/Divorced 42 (15.85) 12 (20.0)
Widower/Widow 21 (7.9) 5 (8.3)
Educational attainment
Up to standard 8 166 (62.6) 44 (73.3) 0.122
Up to form 6 98 (37.0) 15 (25.0)
University or training college 1 (0.4) 1 (1.7)
Income
0 Kwacha/wk 89 (33.6) 20 (33.3) 0.296
Up to 4000 Kwacha/wk 75 (28.3) 16 (26.7)
4000 to 8000 kwacha/wk 42 (15.85) 10 (16.7)
8000 to 12,000 kwacha/wk 27 (10.2) 2 (3.3)
Over 12,000 kwacha/wk 32 (12.1) 12 (20.0)
Employment status
Formal employment 74 (27.9) 9 (15.0) 0.358
Informal employment/Unemployed 106 (40.5) 29 (48.3)
School/University 7 (2.6) 2 (3.3)
Retired 2 (0.8) 0 (0.0)
Housework 74 (27.9) 20 (33.3)
Sick leave 2 (0.75) 0 (0.0)
Socioeconomic position†
Highest quintile 55 (20.75) 10 (16.7) 0.106
2nd highest quintile 53 (20.0) 17 (28.3)
Middle quintile 57 (21.5) 9 (15.0)
2nd lowest quintile 53 (20.0) 7 (11.7)
Lowest quintile 47 (17.7) 17 (28.3)
CD4 Count
CD4 count $350 89 (33.6) 23 (38.3) 0.943
CD4 count 200–350 68 (25.7) 14 (23.3)
CD4 count 50–200 76 (26.7) 17 (28.3)
CD4 count ,50 13 (4.9) 3 (5.0)
Not done or missing 19 (7.2) 3 (5.0)
WHO clinical stage
Stage 1 64 (24.2) 16 (26.7) 0.031
Stage 2 48 (18.1) 10 (16.7)
Stage 3 45 (17.0) 3 (5.0)
Stage 4 6 (2.3) 0 (0)
Not done or missing 102 (38.5) 31 (51.7)
*Chi squared.
†Socioeconomic position estimated though undertaking principal component analysis of responses to assets and housing environment.
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multivariable analyses: ordinary least squares (OLS) regres-
sion, tobit regression, fractional logit regression, and censored
least absolute deviations (CLAD) regression.29–31 We com-
pared mean squared error (MSE) and mean absolute error
(MAE) statistics between observed and estimated EQ-5D
utility scores to determine the choice of estimator. We also
undertook sensitivity analysis using the UK York A1 tariff32
to investigate the impact of using an alternative tariff to
determine EQ-5D utility scores.
RESULTS
A total of 325 trial residents attended the HIV clinics
for assessment for ART initiation over the study period: 265
after facility-based HTC and 60 after HIVST (Fig. 1). Of the
265 facility-based HTC participants, 20 (7.5%) did not
complete ART assessment procedures, 77 (28.8%) completed
ART assessment but did not meet Malawian eligibility criteria
for initiating ART, and 168 (62.9%) completed ART
assessment procedures and initiated ART. Of the 60 HIVST
participants, 5 (8.3%) did not complete ART assessment
procedures, 19 (31.7%) were not eligible to start ART, and 36
(60.0%) initiated ART. There was no signiﬁcant difference in
the characteristics of ART assessed participants across the 2
groups, except for WHO clinical stage, where there was
a higher proportion of missing data for the HIVST group
(Table 1).
The mean total health provider costs during the
assessment period for ART initiation were US$22.79 for
facility HTC participants and US$19.92 for HIVST partic-
ipants (Table 2). During this period, the mean health provider
costs for clinic consultations were US$3.33 (bootstrap 95%
CI: US$2.17 to US$4.50) lower for the HIVST group. The
mean health provider costs for drug and other medical
treatments received were US$0.74 (bootstrap 95% CI: US
$0.33 to US$1.16) lower for the HIVST group. The mean
health provider costs for investigations performed were not
signiﬁcantly different between the 2 groups. The mean total
health provider cost was US$2.87 (bootstrap 95% CI: US
$1.01 to US$4.73) lower for the HIVST group. During the
assessment period for ART initiation, the mean total direct
nonmedical and indirect costs were US$3.31 for facility HTC
participants and US$2.65 for HIVST participants. The mean
total direct nonmedical and indirect costs were not signiﬁ-
cantly different between the 2 groups. The mean total societal
cost over this period was US$3.54 (bootstrap 95% CI: US
$0.37 to US$6.71) lower for the HIVST group.
The mean total health provider costs during the ﬁrst
year following ART initiation were US$168.65 for facility
HTC participants and US$164.66 for HIVST participants
TABLE 2. ART Assessment Costs by Mode of HIV Testing
(2014 US Dollars)
N Mean (SE)
Mean Differences
(95% CI)*
HIVST vs Facility HTC
Direct health provider cost
(2014 US$)
Clinic consultations†
Facility HTC 265 8.65 (0.32) 23.33 (24.50 to 22.17)
HIVST 60 5.32 (0.49)
Investigations‡
Facility HTC 265 15.05 (0.41) 20.25 (21.37 to 0.87)
HIVST 60 14.80 (0.45)
Treatments§
Facility HTC 265 1.71 (0.12) 20.74 (21.16 to 20.33)
HIVST 60 0.96 (0.17)
Total
Facility HTC 265 22.79 (0.56) 22.87 (24.73 to 21.01)
HIVST 60 19.92 (0.77)
Total direct nonmedical and
indirect cost (2014 US$)
Facility HTC 265 3.31 (0.41) 20.67 (22.65 to 1.31)
HIVST 60 2.65 (0.93)
Total societal cost (2014
US$)
Facility HTC 265 26.10 (0.75) 23.54 (26.71 to 20.37)
HIVST 60 22.57 (1.44)
*Bootstrapped 95% CI.
†Includes cost of clinic visit and consultation with health professional.
‡Includes cost of CD4 count and TB diagnostics.
§Includes cost for cotrimoxazole, condoms, and other medications.
ART, antiretroviral treatment.
TABLE 3. First Year ART Costs by Mode of HIV Testing (2014
US Dollars)
N Mean (SE)
Mean Differences
(95% CI)*
HIVST vs Facility HTC
Direct health provider cost
(2014 US$)
Clinic consultations†
Facility HTC 165 23.91 (1.04) 24.04 (28.68 to 0.60)
HIVST 36 19.88 (2.28)
Investigations‡ +
Treatments§
Facility HTC 165 144.74 (1.29) 20.04 (25.71 to 5.79)
HIVST 36 144.78 (2.74)
Total
Facility HTC 165 168.65 (2.02) 24.00 (212.38 to 4.39)
HIVST 36 164.66 (4.21)
Total direct nonmedical and
indirect cost (2014 US$)
Facility HTC 165 13.26 (2.13) 1.46 (27.99 to 10.91)
HIVST 36 14.72 (4.81)
Total societal cost (2014
US$)
Facility HTC 165 181.91 (3.34) 22.54 (217.74 to 12.67)
HIVST 36 179.38 (7.70)
*Bootstrapped 95%CI.
†Includes cost of clinic visit and consultation with health professional.
‡Costs of investigations combined with costs for treatments, as Malawi HIV
guidelines at time of study were for clinical monitoring and hence few participants had
investigations performed during study period.
§Includes cost for antiretroviral drugs, cotrimoxazole, condoms, and other
medications.
ART, antiretroviral treatment.
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(Table 3). There were no signiﬁcant differences in mean
health provider costs for clinic consultations, mean health
provider costs for treatments and investigations, or for mean
total health provider costs between the 2 groups. The mean
total direct nonmedical and indirect costs during the ﬁrst year
following ART initiation were US$10.44 for facility HTC
participants and US$12.03 for HIVST participants. The mean
total direct nonmedical and indirect costs were not signiﬁ-
cantly different between the 2 groups. The mean total societal
costs during the ﬁrst year following ART initiation were US
$178.46 for facility HTC participants and US$177.55 for
HIVST participants. The mean total societal costs were not
signiﬁcantly different between the 2 groups.
In the multivariable analysis (Table 4), after adjusting
for participants’ socio-demographic characteristics and CD4
count on ART assessment, the mean total provider cost for
ART assessment was US$3.18 (95% CI: US$1.77 to US
$4.59) lower for the HIVST group. The mean total societal
cost for ART assessment was US$3.86 (95% CI: US$1.64 to
US$6.08) lower for the HIVST group. There were no
signiﬁcant differences in mean total provider costs or mean
total societal costs during the ﬁrst year following ART
initiation between facility HTC and HIVST participants.
Appendix C, http://links.lww.com/QAI/A996 provides the
results from the cost analysis in 2014 INT dollars.
The HRQoL outcomes for those who were assessed for
ART, immediately before initiation and at 1-year post-ART
initiation, and the change in HRQoL scores between these
time points, are summarized in Table 5. There were no
signiﬁcant difference in EQ-5D utility and VAS scores
immediately before or 1-year post-ART initiation between
the 2 groups. Participants who were initiated onto ART
experienced improvements in EQ-5D utility and VAS scores.
For facility HTC participants who started ART, EQ-5D utility
scores increased by 0.129 (SE: 0.011) and VAS scores
increased by 9.8 (SE: 1.7). For HIVST participants who
started ART, EQ-5D utility scores increased by 0.139 (SE:
0.027) and VAS scores increased by 10.4 (SE: 4.6). There
were no signiﬁcant differences between the 2 groups with
regard to the change in EQ-5D utility and VAS scores after
ART initiation.
In the multivariable analysis (Table 6), the model
diagnostics showed that the OLS estimator performed as well
or better than the other estimators (Appendix D, http://links.
lww.com/QAI/A996). In the fully adjusted OLS model, there
was no signiﬁcant difference in the mean EQ-5D utility score
by mode of HIV testing. In the fully adjusted OLS model, the
mean EQ-5D utility score was 0.043 (95% CI: 0.008 to 0.079)
lower in individuals whose CD4 count was 50–200 cells/mL
compared with those whose CD4 count was $350 cells/mL on
assessment for ART. The mean EQ-5D utility score was 0.230
(95% CI: 0.163 to 0.296) lower in individuals whose CD4
count was below 50 cells/mL compared with those whose CD4
count was $350 cells/mL on assessment for ART.
DISCUSSION
The main ﬁnding of this study was that the economic
costs of providing HIV care and ART to HIV-positive
individuals identiﬁed through HIVST were comparable to
those identiﬁed through standard facility-based HTC services.
Health-related quality of life was worse among those with
lower CD4 counts, with improvements seen after ART
initiation, irrespective of mode of HIV testing. These ﬁndings
emphasize that once HIV self-testers are linked into HIV
services, their economic outcomes are comparable to those
linked to services after facility-based HTC.
Health provider costs for assessing HIV-positive indi-
viduals for ART initiation were lower for HIV self-testers.
This difference was because of lower health provider costs
TABLE 4. Multivariable Analysis Exploring Relationship Between CD4 Count and Mode of HIV Testing, and ART Assessment and
First Year ART Costs (2014 US Dollars)*
Total Health Provider Cost (2014 US Dollars) Total Societal Cost (2014 US Dollars)
ART Assessment (n = 325) First Year on ART (n = 201) ART Assessment (n = 325) First Year on ART (n = 201)
Coef (95% CI) Coef (95% CI)† Coef (95% CI) Coef (95% CI)†
Mode of HIV testing
Facility HTC Ref Ref Ref Ref
HIVST 23.18 (24.59 to 21.77) 25.28 (211.67 to 1.11) 23.86 (26.08 to 21.64) 24.72 (214.89 to 5.45)
Baseline CD4 count
CD4 count .350 cells/mL Ref Ref Ref Ref
CD4 count 200-350 cells/mL 1.19 (21.43 to 3.82) 22.15 (29.74 to 5.45) 2.58 (21.11 to 6.27) 23.56 (27.71 to 14.84)
CD4 count 50-200 cells/mL 0.57 (21.00 to 2.14) 24.60 (212.56 to 3.35) 1.64 (20.81 to 4.09) 0.98 (27.78 to 9.74)
CD4 count ,50 cells/mL 20.45 (23.31 to 2.40) 23.47 (217.57 to 10.62) 1.00 (23.60 to 5.60) 26.68 (225.74 to 12.38)
Not done or missing 216.01 (217.76 to 214.25) 24.91 (218.15 to 8.34) 216.41 (218.81 to 214.01) 23.53 (224.23 to 17.17)
Constant 23.00 (19.46 to 26.52) 178.19 (163.99 to 192.38) 22.82 (18.32 to 27.32) 189.18 (175.49 to 202.88)
Model adjusted for modality of HTC, CD4 count, age, sex, marital status, educational attainment, income, and wealth quintile.
Total cost = constant + b (Modality of HIV testing) + b (Baseline CD4 count) + b (age) + b (sex) + b (marital status) + b (educational attainment) + b (income) + b (wealth
quintile) + e.
*Findings from Generalized Linear Model with Poisson distribution and Identity link function. Distributional family (Poisson) describes the distribution of the data, whilst the link
function describes the relationship between the linear predictor and the mean of the response (cost).
†Findings from 10 imputed data sets with coefﬁcients calculated using Rubin’s rules.23
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TABLE 5. Health-Related Quality of Life Outcomes Immediately Before and 1-Year After ART Initiation by Mode of HIV Testing
N Mean (SE)
Mean Differences (95% CI)*
HIVST vs Facility HTC
EQ-5D utility score
Facility HTC
ART assessment—all 264 0.836 (0.008) 0.018 (20.020 to 0.056)
HIVST
ART assessment—all 60 0.854 (0.018)
Facility HTC
ART assessment—initiated ART 164 0.837 (0.010) 20.001 (20.055 to 0.054)
HIVST
ART assessment—initiated ART 36 0.836 (0.025)
Facility HTC
One year post-ART† 165 0.965 (0.006) 0.010 (20.017 to 0.037)
HIVST
One-year post-ART† 36 0.975 (0.011)
Facility HTC
Change on ART† 165 0.129 (0.011) 0.011 (20.047 to 0.068)
HIVST
Change on ART† 36 0.139 (0.027)
VAS score
Facility HTC
ART assessment 264 73.0 (1.0) 0.5 (24.7 to 5.7)
HIVST
ART assessment 60 73.5 (2.4)
Facility HTC
ART assessment—initiated ART 164 70.9 (1.3) 3.2 (24.2 to 10.6)
HIVST
ART assessment—initiated ART 36 74.1 (3.4)
Facility HTC
One-year post-ART† 165 80.8 (1.4) 3.7 (23.8 to 11.3)
HIVST
One-year post-ART† 36 84.5 (3.6)
Facility HTC
Change on ART† 165 9.8 (1.7) 0.6 (28.9 to 10.0)
HIVST
Change on ART† 36 10.4 (4.6)
EQ-5D utility score (UK tariff)
Facility HTC
ART assessment 264 0.793 (0.012) 0.020 (20.037 to 0.077)
HIVST
ART assessment 60 0.813 (0.028)
Facility HTC
ART assessment—initiated ART 164 0.793 (0.015) 20.009 (20.093 to 0.076)
HIVST
ART assessment—initiated ART 36 0.785 (0.039)
Facility HTC
One year post-ART† 165 0.961 (0.007) 0.013 (20.018 to 0.044)
HIVST
One-year post-ART† 36 0.973 (0.013)
Facility HTC
Change on ART† 165 0.167 (0.016) 0.022 (20.062 to 0.105)
HIVST
Change on ART† 36 0.189 (0.040)
*Bootstrapped 95% CI.
†Findings from 10 imputed data sets with overall differences in mean costs calculated using Rubin’s rules.23
ART, antiretroviral treatment.
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associated with clinic consultations and from provision of
medical treatments. Additionally, fewer HIV self-testers
were clinically assessed as WHO stage 3 or 4. In
comparison with community-based HIV testing services,
individuals accessing HIV testing at health facilities were
often unwell for other reasons (eg, TB) or have more
advanced HIV clinical disease.33 These individuals may
need medical care for management for these other problems
or for investigation to exclude HIV associated illnesses
before initiating ART. Although the cost savings demon-
strated are small at the individual-level, at the population-
level, these could be signiﬁcant with increasing availability
of HIVST.
We estimated the annual health provider cost of
managing a patient on ART to be approximately 2014 US
$170, comparable to previous estimates for Malawi (US
$136 per person per year in 2011).34 Health provider and
societal costs were not affected by modality of HIV testing
before entering HIV care services. Malawi has followed
a public health approach to scaling-up its HIV treatment
services with less reliance on diagnostic tests for clinical
assessment, and therefore the majority of individuals use
comparable levels of healthcare resources.35 We did not ﬁnd
differences in healthcare utilization between the 2 groups.
Although it is reassuring that these costs were comparable,
the ﬁndings highlight opportunities to explore how HIV
treatment should be provided as we move toward universal
access to ART.36
The study demonstrates the relatively high costs
incurred by patients when accessing HIV care. Individuals
incurred a cost of approximately US$3 during their assess-
ment for ART eligibility and US$13 during the ﬁrst year
following ART initiation. The majority of Malawians live on
less than $2 a day.37 Antiretroviral therapy is provided free,
but those accessing care incur costs of transport or because
of taking time off work to attend clinics.38 These costs can
also have a negative impact on adherence to therapy.39,40
ART can be effectively provided in people’s homes through
community distribution models.5,41 Further work is needed
to explore the risks and beneﬁts of home provision
of treatment.
HRQoL as measured by the EQ-5D has been shown
to be responsive to change among HIV-positive patients in
high-income settings,42 but few studies have used this
measure in sub-Saharan African settings.10 The EQ-5D
utility score provides an objective assessment of HRQoL
for cost-utility analysis, with the VAS scores reﬂecting
respondents’ own assessments of their HRQoL. We found
that EQ-5D utility scores to be signiﬁcantly associated
with an HIV-positive individual’s CD4 count, with im-
provements after initiation of ART. Participants also
reported higher VAS scores after ART initiation. The
ﬁndings support the beneﬁcial impact of ART on both
quality and quantity of life and illustrate the importance of
reaching those not in care before their disease advances.
The mode of HIV testing had no independent impact on
HRQoL outcomes.
This study is not without its limitations. The numbers
recruited into the study were small, and many were lost to
follow-up. Although we undertook multiple imputation to
account for this, our ﬁndings may be limited because those
lost to follow-up are potentially a sicker population, with
poorer HRQoL, and, had they remained in care, higher
healthcare resource use. We were not able to include
healthcare resources used as a result of hospitalization
because there was no routine medical record keeping or
linking of records between community, outpatient, and
inpatient services. Furthermore, some of the unit costs
estimated for the healthcare resource inputs, for example
costs of consultations with a healthcare worker, represent
average costs for average reported duration of consulta-
tions. These information system issues reduced our ability
to detect differences in economic outcomes, but are
unlikely to bias our ﬁndings.
TABLE 6. Multivariable Analysis Exploring Relationship Between CD4 Count, Mode of HIV Testing and Pre-ART EQ-5D Utility
Score*
EQ-5D Utility Score (Zimbabwean Tariff) EQ-5D Utility Score (UK Tariff)†
Coef (95% CI) Coef (95% CI)
Modality of HIV testing
Facility HTC Ref Ref
HIVST 0.022 (20.015 to 0.058) 0.026 (20.028 to 0.080)
Baseline CD4 count
CD4 count $350 Ref Ref
CD4 count 200–350 20.011 (20.048 to 0.026) 20.021 (20.075 to 0.033)
CD4 count 50–200 20.043 (20.079 to 20.008) 20.057 (20.110 to 20.004)
CD4 count ,50 20.230 (20.296 to 20.163) 20.371 (20.469 to 20.272)
Not done or missing 20.019 (20.079 to 0.040) 20.035 (20.122 to 0.053)
Constant 0.878 (0.801 to 0.956) 0.834 (0.719 to 0.948)
Model adjusted for modality of HTC, CD4 count, age, sex, marital status, educational attainment, income, and wealth quintile.
Utility score = constant + b (Modality of HIV testing) + b (Baseline CD4 count) + b (age) + b (sex) + b (marital status) + b (educational attainment) + b (income) + b (wealth
quintile) + e.
*Findings from OLS estimator.
†Findings from sensitivity analysis.
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A further limitation is that the EQ-5D tool only
evaluates HRQoL across 5 health dimensions and may
therefore not capture all relevant aspects of HRQoL. The
lack of a Malawian tariff led us to use the Zimbabwean tariff
to derive EQ-5D-3L utility scores. However, the EQ-5D tool
is widely used for health economic analyses, and it is
accepted practice to use tariffs from another country where
none exists for the country of interest provided the 2
populations would value health comparably.15 A ﬁnal study
limitation is that the recent change in ART initiation guide-
lines36 means that we are unable to comment on the economic
outcomes of those who would in the future start treatment
with early HIV disease.
In conclusion, we found that once HIV self-testers
link into HIV treatment services, the costs of providing
HIV care and improvements in HRQoL from ART are no
different to those identiﬁed through facility-based HTC.
The ﬁndings add to the growing literature supporting the
scale-up of HIVST in the region. Full economic evalua-
tions are needed to explore whether implementing HIVST
is cost-effective. Our assessments of economic costs and
preference-based HRQoL outcomes can help inform
such analyses.
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